Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 190 participants.
Also called NCT06762223
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 190 participants
- Sponsor
- Xiqiao Zhou
- Registry
-
NCT06762223
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06762223. Randomized; triple masking; primary purpose treatment. Start 2024-12-31 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
- Condition
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Henagliflozin 10 mg daily
- Intervention (Drug)
- Metformin 1700 mg daily
- Intervention (Other)
- Placebo of Henagliflozin
- Lead sponsor
- Xiqiao Zhou
- Collaborator
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06762223- Content hash
4146b0514aec4c569d6fb81d193a173821b89fc4fb1be838c16ea75df26367a7